Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease

Fig. 4

Degradation of Aβ in vitro by recombinant NEP proteins. Wt-Aβ1-40, wt-Aβ1-42 or arctic-Aβ1-42 peptides incubated with PBS, sNEP, sNEP-scFc-scFv8D3 or muNEP-scFc-scFv8D3 for 2.5, 24, 48 or 72 h at 37 °C. Degradation of Aβ measured in the different mixtures using sandwich ELISA that detects both monomers and aggregates. Two concentration ratios of Aβ/NEP proteins were used. A Aβ1-40 2.5 μM/NEP proteins 0.5 μM. B Aβ1-40 0.5 μM/NEP proteins 0.5 μM. C Aβ1-42 2.5 μM/NEP proteins 0.5 μM. D Aβ1-42 0.5 μM/NEP proteins 0.5 μM. E Arctic Aβ1-42 2.5 μM/NEP proteins 0.5 μM. F Arctic Aβ1-42 0.5 μM/NEP proteins 0.5 μM. Data are normalized to the Aβ/PBS treatment at 0 h. Results presented as mean ± SD. One-way ANOVA with Bonferroni’s multiple comparison test was applied (n = 2) (p > 0.05 = ns; p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = ***)

Back to article page